鼠肉瘤病毒癌基因突变非小细胞肺癌靶向治疗研究进展

Abstract
Figure/Table
References (42)
Related Citation (15)

Download: PDF (0 KB) HTML (45 KB)
Export: BibTeX | EndNote (RIS)

Abstract Kirsten rat sarcoma viral oncogene (KRAS) mutation is one of the most common driver gene mutations in non-small cell lung cancer.Although KRAS mutation was discovered decades ago,target therapy of non-small cells with KRAS mutations has been a bottleneck due to their unique biological characteristics.However, the emergence of new KRAS G12C inhibitors broke this deadlock and further developed targeted therapy for non-small cell lung cancer with mutations in the KRAS gene.The research mechanism of targeting KRAS mutant non-small cell lung cancer at home and abroad is mainly to inhibit membrane localization, directly inhibit KRAS gene, target inhibition of KRAS downstream signals, and inhibit KRAS mutation co-lethal genes.This review summarizes the research progress of targeted therapy for non-small cell lung cancer with mutations in the KRAS gene, so that clinicians can have a deeper understanding of targeted therapy for this particular type of non-small cell lung cancer.

Key words： Kirsten rat sarcoma viral oncogene mutation Kirsten rat sarcoma viral oncogene G12C inhibitors Nonsmall cell lung cancer Target therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DAI Nan-li
	XIANG Ming-jun
	DU Wei
	XIAO Ze-min

Cite this article:

DAI Nan-li,XIANG Ming-jun,DU Wei, et al. Research progress on targeted therapy of Kirsten rat sarcoma virus oncogene mutation in non-small cell lung cancer[J]. 中国当代医药, 2021, 28(10): 28-31转39.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I10/28

[1]	Friedlaender A，Banna G，Malapelle U，et al.Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma：Where Are We Today?[J].Front Oncol，2019，9：166.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2020[J].CA Cancer J Clin，2020，70（1）：7-30.
[15]	Nagasaka M，Li Y，Sukari A，et al.KRAS G12C Game of Thrones，which direct KRAS inhibitor will claim the iron throne?[J].Cancer Treat Rev，2020，84：101974.
[20]	Yang H，Liang SQ，Schmid RA，et al.New Horizons in KRAS-Mutant Lung Cancer：Dawn After Darkness[J].Front Oncol，2019，9：953.
[3]	Friedlaender A，Drilon A，Weiss GJ，et al.KRAS as a druggable target in NSCLC：Rising like a phoenix after decades of development failures[J].Cancer Treat Rev，2020，85：101978.
[4]	Ghimessy A，Radeczky P，Laszlo V，et al.Current therapy of KRAS-mutant lung cancer[J].Cancer and Metastasis Rev，2020，39（4）：1159-1177.
[5]	Román M，Baraibar I，López I，et al.KRAS oncogene in non-small cell lung cancer：clinical perspectives on the treatment of an old target[J].Mol Cancer，2018，17（1）：33.
[6]	Santos E，Martin-Zanca D，Reddy EP，et al.Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient[J].Science，1984，223（4637）：661-664.
[7]	Wood K，Hensing T，Malik R，et al.Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer：A Review[J].JAMA Oncol，2016，2（6）：805-812.
[8]	Garrido P，Olmedo ME，Gómez A，et al.Treating KRAS-mutant NSCLC：latest evidence and clinical consequences[J].Ther Adv Med Oncol，2017，9（9）：589-597.
[9]	Jia Y，Jiang T，Li X，et al.Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer[J].Oncol Lett，2017，14（6）：6525-6532.
[10]	Nussinov R，Jang H，Tsai CJ，et al.Intrinsic protein disorder in oncogenic KRAS signaling[J].Cell Mol Life Sci，2017，74（17）：3245-3261.
[11]	Adjei AA，Mauer A，Bruzek L，et al.Phase Ⅱstudy of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer[J].J Clin Oncol，2003，21（9）：1760-1766.
[12]	Riely GJ，Johnson ML，Medina C，et al.A phase Ⅱtrial of Salirasib in patients with lung adenocarcinomas with KRAS mutations[J].J Thorac Oncol，2011，6（8）：1435-1437.
[13]	Tomasini P，Walia P，Labbe C，et al.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer[J].Oncologist，2016，21（12）：1450-1460.
[14]	Cox AD，Fesik SW，Kimmelman AC，et al.Drugging the undruggable RAS： Mission possible?[J].Nat Rev Drug Discov，2014，13（11）：828-851.
[16]	Janes MR，Zhang J，Li LS，et al.Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor[J].Cell，2018，172（3）：578-589.
[17]	Fakih M，O′Neil B，Price TJ，et al.Phase 1 study evaluating the safety，tolerability，pharmacokinetics（PK），and efficacy of AMG 510，a novel small molecule KRASG12C inhibitor，in advanced solid tumors[J].J Clin Oncol，2019，37：3003.
[18]	Jnne PA，Papadopoulous K，Ou I，et al.A Phase 1 clinical trial evaluating the pharmacokinetics（PK），safety，and clinical activity of MRTX849，a mutant-selective small molecule KRAS G12C inhibitor，in advanced solid tumors[C].AACRNCI-EORTC International Conference on Molecular Targets，Boston，America：2019.
[19]	Feng H，Zhang Y，Bos PH，et al.K-Ras G12D Has a Potential Allosteric Small Molecule Binding Site[J].Biochemistry，2019，58（21）：2542-2554.
[21]	Blasco RB，Francoz S，Santamaría D，et al.c-Raf，but not B-Raf，is essential for development of K-Ras oncogenedriven non-small cell lung carcinoma[J].Cancer Cell，2011，19（5）：652-663.
[22]	Terrell EM，Durrant DE，Ritt DA，et al.Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling[J].Mol Cell，2019，76（6）：872-884.
[23]	Blasco MT，Navas C，Martín-Serrano G，et al.Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF[J].Cancer Cell，2019，35（4）：573-587.
[24]	Matikas A，Mistriotis D，Georgoulias V，et al.Targeting KRAS mutated non-small cell lung cancer：A history of failures and a future of hope for a diverse entity[J].Crit Rev Oncol Hematol，2017，110：1-12.
[25]	Jnne PA，Smith I，McWalter G，et al.Impact of KRAS codon subtypes from a randomised phase Ⅱtrial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer[J].Br J Cancer，2015，113（2）：199-203.
[26]	Jnne PA，van den Heuvel MM，Barlesi F，et al.Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer：The SELECT -1 Randomized Clinical Trial[J].JAMA，2017，317（18）：1844-1853.
[27]	Blumenschein GR Jr，Smit EF，Planchard D，et al.A randomized phase Ⅱ study of the MEK1/MEK2 inhibitor trametinib（GSK1120212）comparedwithdocetaxelinKRASmutant advanced non-small-cell lung cancer（NSCLC）[J].Ann Oncol，2015，26（5）：894-901.
[28]	Aredo JV，Padda SK.Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine[J].Curr Treat Options Oncol，2018，19（8）：43.
[29]	Yamamoto N，Fujiwara Y，Tamura K，et al.Phase Ⅰa/Ⅰb study of the pan-class ⅠPI3K inhibitor pictilisib（GDC-0941） administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer[J].Invest New Drugs，2017，35（1）：37-46.
[30]	Vansteenkiste JF，Canon JL，De Braud F，et al.Safety and Efficacy of Buparlisib（BKM120） in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer：Resultsfrom the Phase ⅡBASALT-1 Study[J].J Thorac Oncol，2015，10（9）：1319-1327.
[31]	Tan AC.Targeting the PI3K/Akt/mTOR pathway in nonsmall cell lung cancer（NSCLC）[J].Thorac Cancer，2020，11：511-518.
[32]	Riely G，Brahmer J，Planchard D，et al.A randomized discontinuation phase Ⅱtrial of ridaforolimus in non-small cell lung cancer（NSCLC）patients with KRAS mutations[J].J Clin Oncol，2012，30：7531.
[33]	Aguirre AJ，Hahn WC.Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers[J].Cold Spring Harb Perspect Med，2018，8（8）：a031518.
[34]	Kumar MS，Hancock DC，Molina-Arcas M，et al.The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer[J].Cell，2012，149（3）：642-655.
[35]	Wu C，Wang S，Xu C，et al.WT 1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc[J].Cell Physiol Biochem，2015，35（2）：647-662.
[36]	Barbie DA，Tamayo P，Boehm JS，et al.Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1[J].Nature，2009，462（7269）：108-112.
[37]	Drilon A，Schoenfeld AJ，Arbour KC，et al.Exceptional responders with invasive mucinous adenocarcinomas：a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers[J].Cold Spring Harb Mol Case Stud，2019，5（2）：a003665.
[38]	Mao CQ，Xiong MH，Liu Y，et al.Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery[J].Mol Ther，2014，22（5）：964-973.
[39]	Goldman JW，Mazieres J，Barlesi F，et al.A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage ⅣNSCLC with KRAS mutation：JUNIPER[J].J Clin Oncol，2018，36（15）：9025.
[40]	Shapiro GI，Hilton J，Gandi L，et al.Abstract CT046：PhaseⅠdose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant solid tumors[J].Cancer Res，2017，77：CT046.
[41]	Ramalingam S，Goss G，Rosell R，et al.A randomized phaseⅡstudy of ganetespib，a heat shock protein 90 inhibitor，in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer（GALAXY-1）[J].Ann Oncol，2015，26（8）：1741-1748.
[42]	Felip E，Barlesi F，Besse B，et al.Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer[J].J Thorac Oncol，2018，13（4）：576-584.